Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reed F Beall

Showing results (11-20 of 62) with videos related to

Pageof 7
Sort By:
Plos One|October 22, 2021
The private versus public contribution to the biomedical literature during the COVID-19, Ebola, H1N1, and Zika public health emergenciesReed F Beall, Javad Moradpour, Aidan Hollis
Open Medicine : a Peer-Reviewed, Independent, Open-Access Journal|November 27, 2014
Pan-Canadian overpricing of medicines: a 6-country study of cost control for generic medicinesReed F Beall, Jason W Nickerson, Amir Attaran
Journal of Managed Care & Specialty Pharmacy|January 31, 2019
New Drug Formulations and Their Respective Generic Entry DatesReed F Beall, Aaron S Kesselheim, Ameet Sarpatwari
Journal of Pharmaceutical Policy and Practice|May 4, 2016
Upstream solutions for price-gouging on critical generic medicinesAdam R Houston, Reed F Beall, Amir Attaran
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 29, 2021
Premarket Development Times for Innovative Vaccines--To What Extent Are the Coronavirus Disease 2019 (COVID-19) Vaccines Outliers?Reed F Beall, Aaron S Kesselheim, Aidan Hollis
Nature Biotechnology|June 20, 2019
Pre-market development times for biologic versus small-molecule drugsReed F Beall, Thomas J Hwang, Aaron S Kesselheim
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 4, 2018
A Method for Approximating Future Entry of Generic DrugsReed F Beall, Jonathan J Darrow, Aaron S Kesselheim
Health Policy (Amsterdam, Netherlands)|October 12, 2019
How will recent trade agreements that extend market protections for brand-name prescription pharmaceuticals impact expenditures and generic access in Canada?Reed F Beall, Lorian Hardcastle, Fiona Clement, et al.
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|April 18, 2019
Approximating Future Generic Entry for New DrugsReed F Beall, Jonathan J Darrow, Aaron S Kesselheim
Applied Health Economics and Health Policy|August 25, 2018
The Generic Drug Industry Embraces a Faster, Cheaper Pathway for Challenging PatentsJonathan J Darrow, Reed F Beall, Aaron S Kesselheim
Pageof 7

Showing results (11-20 of 62) with videos related to

Sort By:
Pageof 7
Plos One|October 22, 2021
The private versus public contribution to the biomedical literature during the COVID-19, Ebola, H1N1, and Zika public health emergenciesReed F Beall, Javad Moradpour, Aidan Hollis
Open Medicine : a Peer-Reviewed, Independent, Open-Access Journal|November 27, 2014
Pan-Canadian overpricing of medicines: a 6-country study of cost control for generic medicinesReed F Beall, Jason W Nickerson, Amir Attaran
Journal of Managed Care & Specialty Pharmacy|January 31, 2019
New Drug Formulations and Their Respective Generic Entry DatesReed F Beall, Aaron S Kesselheim, Ameet Sarpatwari
Journal of Pharmaceutical Policy and Practice|May 4, 2016
Upstream solutions for price-gouging on critical generic medicinesAdam R Houston, Reed F Beall, Amir Attaran
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 29, 2021
Premarket Development Times for Innovative Vaccines--To What Extent Are the Coronavirus Disease 2019 (COVID-19) Vaccines Outliers?Reed F Beall, Aaron S Kesselheim, Aidan Hollis
Nature Biotechnology|June 20, 2019
Pre-market development times for biologic versus small-molecule drugsReed F Beall, Thomas J Hwang, Aaron S Kesselheim
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 4, 2018
A Method for Approximating Future Entry of Generic DrugsReed F Beall, Jonathan J Darrow, Aaron S Kesselheim
Health Policy (Amsterdam, Netherlands)|October 12, 2019
How will recent trade agreements that extend market protections for brand-name prescription pharmaceuticals impact expenditures and generic access in Canada?Reed F Beall, Lorian Hardcastle, Fiona Clement, et al.
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|April 18, 2019
Approximating Future Generic Entry for New DrugsReed F Beall, Jonathan J Darrow, Aaron S Kesselheim
Applied Health Economics and Health Policy|August 25, 2018
The Generic Drug Industry Embraces a Faster, Cheaper Pathway for Challenging PatentsJonathan J Darrow, Reed F Beall, Aaron S Kesselheim
Pageof 7